

Imaging Timing After Surgery for Glioblastoma (INTERVAL GB)

INTERVAL-GB Collaborative

DOI:

[10.1016/j.bas.2023.102127](https://doi.org/10.1016/j.bas.2023.102127)

License:

Creative Commons: Attribution-NonCommercial-NoDerivs (CC BY-NC-ND)

Document Version

Publisher's PDF, also known as Version of record

Citation for published version (Harvard):

INTERVAL-GB Collaborative 2023, 'Imaging Timing After Surgery for Glioblastoma (INTERVAL GB): A multi-centre, UK and Ireland retrospective cohort study', *Brain and Spine*, vol. 3, no. Supplement 1, 102127. <https://doi.org/10.1016/j.bas.2023.102127>

[Link to publication on Research at Birmingham portal](#)

General rights

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.


When citing, please reference the published version.

Take down policy

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to the work immediately and investigate.

Optional Image



	N	No (N=311)	Yes (N=69)	Test Statistic
Lesion Localization	380			X22=9.44, P=0.01 ²
Precentral		144/311	18/69	
Postcentral		58/311	18/69	
Temporoinsular		109/311	33/69	
Distance of the Enhancing Nodule from Ventricle	380			X26=34.00, P<0.01 ²
Continuous		65/311	35/69	
< 0.5 cm		33/311	12/69	
0.5 - 1 cm		46/311	5/69	
1 - 1.5 cm		44/311	3/69	
1 - 2 cm		39/311	4/69	
2 - 2.5 cm		39/311	4/69	
> 2.5 cm		45/311	6/69	
Tumor type	380			X27=8.47, P=0.29 ²
Glioblastoma		266/311	58/69	
Astrocytoma		25/311	3/69	
Gliosarcoma		2/311	1/69	
Oligoastrocytoma		1/311	0/69	
Oligodendroglioma		15/311	5/69	
Xanthoastrocytoma		1/311	1/69	
Anaplastic Ependymoma		1/311	0/69	
Anaplastic Ganglioglioma		0/311	1/69	
WHO grade 4	380	265/311	57/69	X21=0.30, P=0.59 ²
Presence of MGMT Methylation	380	127/311	25/69	X21=0.50, P=0.48 ²
IDH1 Mutated	380	38/311	8/69	X21=0.02, P=0.89 ²
IDH2 Mutated	380	2/311	1/69	X21=0.47, P=0.49 ²
Ki-67	298	20.0 32.0 60.0	20.0 35.0 70.0	F _{1,296} =0.71, P=0.40 ³
Presence of Meningeal Involvement	380	11/311	2/69	X21=0.07, P=0.79 ²
Presence of Ependymal Involvement	380	12/311	9/69	X21=9.13, P=0.01 ²
Corpus Callosum Involvement	380	29/311	10/69	X21=1.64, P=0.20 ²
LD Positioning	380	2/311	0/69	X21=0.45, P=0.50 ²
EVD positioning	380	0/311	6/69	X21=27.48, P<0.01 ²
EOR	380			X22=2.53, P=0.28 ²
STR		38/311	11/69	
GTR		249/311	56/69	
SupTR		24/311	2/69	

1583

**BRAIN AND SPINE 3 (2023) 101794 102127
IMAGING TIMING AFTER SURGERY FOR GLIOBLASTOMA (INTERVAL GB):
A MULTI-CENTRE, UK AND IRELAND RETROSPECTIVE COHORT STUDY**

Emily Rose Bligh¹, Conor Gillespie², Michael T.C. Poon³, Georgios Solomou⁴, Melissa Gough⁵, Abdurrahman I. Islam⁶, Christopher P. Millward⁷, Ola Rominiyi⁸, Rasheed Zakaria⁹, Stephen J. Price⁴, Colin Watts¹⁰, Sophie Camp¹¹, Thomas C. Booth¹², Gerard Thompson¹³, Samantha J. Mills¹⁴, Adam Waldman¹⁵, Paul Brennan¹⁵, Michael D. Jenkinson⁷, INTERVAL-GB Collaborative¹⁶ ¹Department of Neurosurgery, Queen Elizabeth University Hospital, Glasgow, United Kingdom; ²Department of Neurosurgery, The Walton Centre NHS Foundation Trust, Liverpool, UK, United Kingdom; ³Usher Institute, The University of Edinburgh, Edinburgh, UK, United Kingdom; ⁴Department of Clinical Neurosciences, University

of Cambridge, Cambridge, UK, United Kingdom; ⁵ Department of Neurosurgery, Royal Victoria Infirmary, Newcastle upon Tyne, UK, United Kingdom; ⁶ Division of Neuroscience and Experimental Psychology, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK, United Kingdom; ⁷ Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, UK, United Kingdom; ⁸ Department of Oncology & Metabolism, The University of Sheffield, Sheffield, UK, United Kingdom; ⁹ Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, UK, United Kingdom; ¹⁰ Institute of Cancer and Genomic Studies, University of Birmingham, Birmingham, UK, United Kingdom; ¹¹ Department of Neurosurgery, Imperial College Healthcare NHS Trust, London, UK, United Kingdom; ¹² School of Biomedical Engineering & Imaging Sciences, King's College London, London, UK, United Kingdom; ¹³ Edinburgh Neuro-oncology Translational Imaging Research (ENTIRE), Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK, United Kingdom; ¹⁴ Department of Neuroradiology, The Walton Centre NHS Foundation Trust, Liverpool, UK, United Kingdom; ¹⁵ Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK, United Kingdom; ¹⁶ Neurology and Neurosurgery Interest Group (NANSIG), London, UK, United Kingdom

Oral e-Poster Presentations - Booth 3: Neuro-Oncology A (Malignant glioma), September 25, 2023, 1:00 PM - 2:30 PM

Background: The benefit of regular, scheduled follow-up MRI on glioblastoma patient management and outcomes is unclear. Our aim was to investigate national follow-up MRI surveillance practice after surgery for glioblastoma, assess compliance with recommendations from the National Institute for Health and Care Excellence (NICE), and determine the association with overall survival (OS) and progression-free survival (PFS).

Methods: Multi-centre retrospective observational cohort study of histopathologically confirmed glioblastoma (operated August 2018-February 2019) who received any adjuvant oncological treatment. Follow-up MRI schedules, indications, and clinical outcomes were collected. Primary objective was to assess compliance with NICE recommendations (Post-operative scan <72 hrs, MRI every 3-6 months). Secondary objectives were OS and PFS.

Results: 754 patients from 26 neuro-oncology centres were included. Most patients had post-operative MRI <72 hours of surgery (88.1%, N=407/462). 28.1% of patients had follow-up MRI in accordance with NICE recommendations (N=212/754). Median follow-up period was 10.5 months (IQR 5.3-19.4 months). Median overall survival was 15.1 months (95% CI 12.9-17.3) in the scheduled MRI group and 9.1 months (95% CI 7.8-10.4) in the non-compliant group. On multivariable cox regression analysis, regular, scheduled MRI was independently associated with longer overall survival (HR 1.67, 95% CI 1.33-2.10, P<0.001), but not PFS (HR 1.20, 95% CI 0.98-1.47, P=0.074). Having three or more scheduled scans in the first 12 months of follow-up was independently associated with increased OS (HR 2.03, 95% CI 1.41-2.94, P<0.001) and PFS (HR 1.67, 95% CI 1.25-2.23, P<0.001).

Conclusions: Following regular scheduled surveillance follow-up MRI for glioblastoma is associated with longer overall survival. Prospective trials are needed to determine whether regular or symptom-directed MRI influences survival outcomes and quality of life.

38

**BRAIN AND SPINE 3 (2023) 101794 102128
THE ROLE OF P16 IMMUNOHISTOCHEMISTRY AS A PROGNOSTIC BIOMARKER IN MENINGIOMAS**

Felix Behling¹, Maria-Elisa Di Francesco¹, Christina-Katharina Fodi¹, Jürgen Honegger¹, Marcos Tatagiba¹, Ghazaleh Tabatabai¹, Jens Schittenhelm¹. ¹ University Hospital Tübingen, Tübingen, Germany

Oral e-Poster Presentations - Booth 3: Neuro-Oncology B (Meningiomas & Metastasis), September 26, 2023, 1:00 PM - 2:30 PM

Background: Despite best clinical management many patients suffering from meningioma experience tumor recurrence. During the last decades efforts have been made to improve the prognostic stratification regarding meningioma recurrence. In many other tumor entities, loss of p16 is associated with tumor progression. Evaluation of p16 staining for routine diagnostics and prognostic significance to identify meningiomas at risk for recurrence is of clinical interest.

Methods: In this retrospective single-institutional study the immunohistochemical staining for p16 was analyzed in 397 paraffin-embedded meningioma samples. The distribution and association with tumor grading, clinical data and progression-free survival according to follow-up MRI were assessed.

Results: Of 397 meningioma samples 69 tumors were immunopositive for p16